Af­ter sput­ter­ing on the launch pad, No­vavax fi­nal­ly gets its EUA ap­pli­ca­tion in. Does it mat­ter?

No­vavax has fi­nal­ly met one of its self-im­posed dead­lines for the long-await­ed EUA fil­ing for its Covid-19 vac­cine.

Af­ter re­peat­ed­ly dis­ap­point­ing in­vestors while rais­ing ques­tions about its abil­i­ty to man­u­fac­ture the vac­cine to FDA stan­dards, No­vavax an­nounced late Mon­day that the EUA has fi­nal­ly been dis­patched to the agency.

For No­vavax, the pan­dem­ic has been a god­send, of­fer­ing the biotech a shot at its first ap­proval — and this for what has been an enor­mous new mar­ket. But while No­vavax floun­dered re­peat­ed­ly at the FDA, Pfiz­er/BioN­Tech and Mod­er­na — which yes­ter­day fol­lowed up with their for­mal ap­proval — cruised ahead with 2 new mR­NA vac­cines that have dom­i­nat­ed the US mar­ket, with J&J’s one shot jab in the mix.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER